Beneficial effects of novel aureobasidium pullulans strains produced beta-1,3-1,6 glucans on interleukin-6 and D-dimer levels in COVID-19 patients; results of a randomized multiple-arm pilot clinical study.
Biomed Pharmacother
; 145: 112243, 2022 Jan.
Artículo
en Inglés
| MEDLINE | ID: covidwho-1432984
Preprint
Este artículo de revista científica es probablemente basado en un preprint previamente disponible, por medio del reconocimiento de similitud realizado por una máquina. La confirmación humana aún está pendiente.
Ver preprint
Este artículo de revista científica es probablemente basado en un preprint previamente disponible, por medio del reconocimiento de similitud realizado por una máquina. La confirmación humana aún está pendiente.
Ver preprint
ABSTRACT
OBJECTIVE:
In this pilot clinical study, we report the beneficial effects of beta glucans derived from two strains AFO-202 and N-163 of a black yeast Aureobasidium pullulans on the biomarkers for cytokine storm and coagulopathy in COVID-19 patients.METHODS:
A total of 24 RT-PCR positive COVID-19 patients were recruited and randomly divided into three groups (Gr) Gr. 1 control (n = 8) - Standard treatment; Gr. 2 Standard treatment + AFO-202 beta glucan (n = 8); and Gr. 3, Standard treatment + combination of AFO-202 and N-163 beta glucans (n = 8) for 30 days.RESULTS:
There was no mortality or requirement of ventilation of the subjects in any of the groups. There was a decrease in D-Dimer values (751 ng/ml to 143.89 ng/ml) and IL-6 values (7.395-3.16 pg/ml) in Gr. 1 in 15 days but the levels increased to abnormal levels on day 30 (D-Dimer 202.5 ng/ml; IL-6 55.37 pg/ml); which steadily decreased up to day 30 in groups 2 (D-dimer 560.99 ng/dl to 79.615; IL-6 26.18-3.41 pg/ml) and 3 (D-dimer 1614 ng/dl to 164.25 ng/dl; IL-6 6.25-0.5 pg/ml). The same trend was observed with ESR. LCR and LeCR increased while NLR decreased significantly in Gr. 3. CD4 + and CD8 + T cell count showed relatively higher increase in Gr.3. There was no difference in CRP within the groups.CONCLUSION:
As these beta glucans are well known food supplements with a track record for safety, larger multi-centric clinical studies are recommended to validate their use as an adjunct in the management of COVID-19 and the ensuing long COVID-19 syndrome.Palabras clave
Texto completo:
Disponible
Colección:
Bases de datos internacionales
Base de datos:
MEDLINE
Asunto principal:
Productos de Degradación de Fibrina-Fibrinógeno
/
Interleucina-6
/
Beta-Glucanos
/
Síndrome de Liberación de Citoquinas
/
Aureobasidium
/
COVID-19
/
Tratamiento Farmacológico de COVID-19
Tipo de estudio:
Estudios diagnósticos
/
Estudio experimental
/
Estudio pronóstico
/
Ensayo controlado aleatorizado
Tópicos:
Covid persistente
/
Medicina tradicional
Límite:
Femenino
/
Humanos
/
Masculino
/
Middle aged
Idioma:
Inglés
Revista:
Biomed Pharmacother
Año:
2022
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS